®
It’s About Survival
ImmuCyst Disease-free survival Adapted from ImmuCyst® Product Monograph and Lamm et al., 2000. * Analysis of 660 patients with recurrent stage Ta, T1 or CIS TCC (transitional cell carcinoma) randomized after 6-week induction to observation or maintenance BCG instillations.2 ImmuCyst maintenance therapy1-3 ® :
ImmuCyst®
is indicated for intravesical use in in situ
References: 1. ImmuCyst® Product Monograph, Sanofi Pasteur, January 2010. 2. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin
immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol. 2000;163:1124-1129. 3. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol. 2000;37(Suppl 1):9-15.
is a registered trademark of Sanofi Pasteur Limited. Copyright © 2011 Sanofi Pasteur Limited. All rights reserved.
ImmuCyst® 177-005 3.0 years ®
maintenance therapy
*: Induction only (n=192) Induction + maintenance (n=192) more than doubled 6.4 years (p<0.0001)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76